title: What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
abstract: OBJECTIVE
  We investigated predicting factors for the therapeutic effects of dutasteride in patients with lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) based on a urodynamic study (UDS).
  
  
  METHODS
  This was a single-center, prospective study involving 120 male outpatients with LUTS. They received 0.5 mg of dutasteride per day for 12 months. IPSS, OABSS, IPSS-QOL, and UDS were used for assessing subjective and objective symptoms prior to and 12 months after administration. Patient's age, PSA level, prostate volume, IPSS, OABSS, maximum flow rate, and post-void residual urine volume, and intravesical prostatic protrusion (IPP) were set as pre-administration parameters to predict the therapeutic effect. We evaluated the relationship between these parameters and the therapeutic effects, depending on the extent of improvement of IPSS and bladder outlet obstruction (BOO).
  
  
  RESULTS
  A total of 104 patients with mean age of 68.9 years and mean prostate volume of 58.9 mL were included in the analysis. Thirty-two patients (30.8%) showed an insignificant IPSS improvement of <25%, while 41 patients (39.4%) showed excellent IPSS improvement of 50% or greater. On the multivariate logistic regression analysis, IPP (95% confidence interval: 0.606-0.810) was found to be the only factor related to the improvement in IPSS. Additionally, the multiple linear regression analysis demonstrated that IPP was the most powerful factor for predicting improvement of BOO (r = -0.51, P < 0.001).
  
  
  CONCLUSIONS
  IPP is considered a useful predictor of the therapeutic effects of dutasteride for both subjective symptoms and BOO.
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Matsukawa
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Kato
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Funahashi
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Majima
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Tokunori
authors.initials: T
authors.lastname: Yamamoto
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Momokazu
authors.initials: M
authors.lastname: Gotoh
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D000068538:Dutasteride / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000068538:Dutasteride
keywords: 5α-reductase inhibitor; benign prostatic hyperplasia; intravesical prostatic protrusion; predicting factors; therapeutic effects; urodynamics